Over 3,000 “Health Impact Events” After COVID-19 mRNA Vaccinations
December 22, 2020 | Risk & Failure Reports
|
Between Dec. 11 and 18, 2020, the U.S. Food and Drug Administration (FDA) granted Pfizer/BioNTech and Moderna pharmaceutical companies an Emergency Use Authorization (EUA) to distribute COVID-19 vaccines using messenger RNA (mRNA) technology that to date has not been licensed for use in humans. Although the Advisory Committee on Immunization Practices (ACIP) of the U.S. Centers for Disease Control and Prevention (CDC)…
|
|
Peruvian Man Suffers Guillain-Barré-like Symptoms After Receiving Sinopharm COVID-19 Vaccine
December 22, 2020 | Risk & Failure Reports
|
On Dec. 11, 2020, Peru’s National Institute of Health (INS) said it was temporarily suspending the Phase 1 clinical trial of an experimental COVID-19 vaccine developed by Sinopharm Group Co. Ltd. of Shanghai, China after one of the participants in the trial who got the vaccine showed difficulty in moving his arms and legs—symptoms of Guillain-Barré syndrome (GBS). In a public statement, the INS said that the “adverse event” was…
|
|